{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:08:42Z","timestamp":1790734122120,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Pionyr","award":["Trial Registration: NCT04691375"],"award-info":[{"award-number":["Trial Registration: NCT04691375"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s10637-024-01419-1","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T15:02:56Z","timestamp":1708354976000},"page":"179-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Kathryn E.","family":"Beckermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babar","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos E.","family":"Kyriakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy F.","family":"Sweis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"issue":"9","key":"1419_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMOA2026982\/SUPPL_FILE\/NEJMOA2026982_DATA-SHARING.PDF","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Ju\u00e1rez VM, Hsieh JJ, Basso U, Shah AY, Su\u00e1rez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, \u017bo\u0142nierek J, ... Motzer RJ (2021) Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New Eng J Med 384(9):829\u2013841. https:\/\/doi.org\/10.1056\/NEJMOA2026982\/SUPPL_FILE\/NEJMOA2026982_DATA-SHARING.PDF","journal-title":"New Eng J Med"},{"issue":"14","key":"1419_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMOA2035716\/SUPPL_FILE\/NEJMOA2035716_DATA-SHARING.PDF","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, Kopyltsov E, M\u00e9ndez-Vidal MJ, Kozlov V, Alyasova A, Hong S-H, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, ... Choueiri TK (2021) Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New Eng J Med 384(14):1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMOA2035716\/SUPPL_FILE\/NEJMOA2035716_DATA-SHARING.PDF","journal-title":"New Eng J Med"},{"issue":"14","key":"1419_CR3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm M-O, ... CheckMate 214 Investigators (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. Eng J Med 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"Eng J Med"},{"issue":"12","key":"1419_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, ... Powles T (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New Eng J Med 380(12):1116\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1816714","journal-title":"New Eng J Med"},{"issue":"3","key":"1419_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/IMM.12976","volume":"155","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Kitamura T (2018) Macrophage targeting: opening new possibilities for cancer immunotherapy. Immunology 155(3):285\u2013293. https:\/\/doi.org\/10.1111\/IMM.12976","journal-title":"Immunology"},{"issue":"6","key":"1419_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/S41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B (2019) Macrophages as regulators of tumor immunity and immunotherapy. Nat Rev Immunol 19(6):369. https:\/\/doi.org\/10.1038\/S41577-019-0127-6","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1419_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/CAS.12314","volume":"105","author":"Y Komohara","year":"2014","unstructured":"Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105(1):1\u20138. https:\/\/doi.org\/10.1111\/CAS.12314","journal-title":"Cancer Sci"},{"key":"1419_CR8","doi-asserted-by":"publisher","first-page":"50946","DOI":"10.1371\/JOURNAL.PONE.0050946","volume":"7","author":"QW Zhang","year":"2012","unstructured":"Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 7(12):e50946. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0050946","journal-title":"PLoS ONE"},{"issue":"11","key":"1419_CR9","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1016\/j.cell.2021.04.038","volume":"184","author":"A Obradovic","year":"2021","unstructured":"Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, Rathmell WK, Jonasch E, Johnson JE, Roth M, Beckermann KE, Rini BI, McKiernan J, Califano A, Drake CG (2021) Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell 184(11):2988\u20133005.e16. https:\/\/doi.org\/10.1016\/j.cell.2021.04.038","journal-title":"Cell"},{"key":"1419_CR10","doi-asserted-by":"publisher","first-page":"109844","DOI":"10.1016\/J.CELREP.2021.109844","volume":"37","author":"M Binnewies","year":"2021","unstructured":"Binnewies M, Pollack JL, Rudolph J, Dash S, Abushawish M, Lee T, Jahchan NS, Canaday P, Lu E, Norng M, Mankikar S, Liu VM, Du X, Chen A, Mehta R, Palmer R, Juric V, Liang L, Baker KP, ... Sriram V (2021) Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep 37(3):109844. https:\/\/doi.org\/10.1016\/J.CELREP.2021.109844","journal-title":"Cell Rep"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01419-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01419-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T12:29:33Z","timestamp":1710851373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01419-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1419"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01419-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KEB received funding to the institution for preclinical work unrelated to this study from Pionyr.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}